Applicants: Universidade de Vigo
The SM 50/10 human monoclonal antibody comprises hybridoma obtained from lymphocytes B of mice immunized with human leucocytes fused with SP 2/0 myeloma cells. Also claimed is a process using the antibody in therapy. CLAIMED PROCESS – The process recognizes human leucocytes and in particular a specific antigen (molecular weight 150-180 Kd.) present in lymphocytes T and B.
More information: Oficina Española de Patentes y Marcas
Associated research lines: Immunotherapy.